Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Cancer Institute (NCI) has granted a small business initiative research (SBIR) grant, under its (NCI-SBIR) program, to Eutropics Pharmaceuticals for the development of a proprietary BH3 profiling diagnostic assay.
Subscribe to our email newsletter
The assay, which provides a biomarker/ diagnostic to know the use of approved therapies for multiple cancer indications, is used as a personalized medicinal treatment in Acute Myelogenous Leukemia (AML) patient management.
The company claimed that assay is also being tested as a companion test for experimental therapies presently under development.
Under the NCI-SBIR contract, the company will validate early results that indicate the predictive utility of the assay.
Eutropics chief executive officer Michael Cardone said,"This award confirms our approach to providing such a test and positions Eutropics to move the technology forward, empowering oncologists with valuable information for providing the most effective care to their patients."
Eutropics scientific advisor Michael Andreeff said there is likelihood that this BH3 profiling technology will be a guiding tool to treat AML.
"We are all looking forward to its validation in the clinical studies proposed in this contract," Andreeff added.